Canbi Pharma Tech Limited

FDA approves presbyopia eye drops

Aug 04, 2025

          LENZ Therapeutics announced today that the US FDA has approved Vizz (Aceclidine ophthalmic solution) 1.44% for the treatment of adult patients with presbyopia. According to the press release, Vizz is the first eye drops based on acetate and used to treat adult presbyopia. The patient uses it once a day, and the therapeutic effect can last up to 10 hours!

 

          Vizz is a preservative free, once daily eye drops designed to provide patients with clear near vision for up to 10 hours. The effective ingredient in this therapy is acetic acid. Acetonidin is a small molecule acetylcholine receptor agonist that can cause pupil constriction to below 2 millimeters, resulting in a pinhole effect and improving near vision. However, compared with other cholinergic receptor agonists, its effect on the iris muscle that controls pupil size is more specific, thereby reducing the contraction of ciliary muscles while shrinking the pupil, lowering the refractive changes of the lens, and avoiding affecting the patient's far vision.

 

          Vizz's approval is mainly based on three randomized, double-blind, controlled phase 3 clinical studies. CLARITY 1 and CLARITY 2 aim to evaluate the safety and efficacy of Vizz once daily for 42 days in 466 subjects; CLARITY 3 was conducted among 217 subjects for a period of 6 months, mainly to evaluate the safety of long-term medication.

 

           In the CLARITY 1 and CLARITY 2 studies, Vizz met all primary and secondary endpoints of near vision improvement, and the results showed that it could take effect within 30 minutes and continuously improve vision for up to 10 hours. The results of near vision improvement in the two studies are highly consistent and reproducible. Vizz showed good tolerability in three CLARITY studies with a cumulative use of over 30000 medication days, and no treatment-related serious adverse events were observed. The most common adverse reactions include irritation at the application site, darkening of vision, and headache, and most of them are mild, transient, and self-healing.

 

<Reprinted from WuXi AppTec>

https://mp.weixin.qq.com/s/KIJh0VWgeC1gBT_Aa-Ex9Q

 

goTop